



CytoTools AG increases its stake in DermaTools Biotech GmbH to nearly 60 %

Darmstadt, 28th June 2018 – The CytoTools AG (ISIN DE000A0KFRJ1), in June 2018, increased its stake to almost 60 % in its existing subsidiary DermaTools Biotech GmbH, within the scope of a capital increase. The company is investing about 1.5 million euros from its successful placement of a convertible bond at the beginning of the month. Thus DermaTools is being given the necessary liquid means to pay for the realization of the next steps, in particular the clinical trial on active substance dosing and the clinical phase III trial in Europe for DermaPro®. DermaPro® is an innovative solution for the treatment of diabetic foot syndrome. It is to be marketed by the Indian license partner, Centaur Pharmaceuticals, in India, after the expected approval of the production facilities in India has been carried out. This should take place this year. „The development and marketing activities in this local market are the exclusive responsibility of our partner“, stressed Dr. Mark Andre Freyberg. „We have received encouraging signals, however, that the plan, as originally conceived, will be implemented already this year.“

This press release contains specific future oriented statements. These reflect the opinion of CytoTools on the date of this release. The actual results achieved by CytoTools could substantially deviate from the future-oriented statements made. CytoTools is not obligated to update these future-oriented statements.

About CytoTools

CytoTools AG is a German biotechnology company focused on translating fundamental biology research on the mechanisms of cell growth and programmed cell death into unique therapies that are designed to treat the cause of the disease rather than the symptoms. The Company has developed a robust and diverse pipeline of disease modifying therapies that comprise proprietary small molecules and biologics. These have the potential to provide new treatment options in dermatology, cardiology and angiology, urology and oncology. CytoTools AG is structured as an investment and holding company and as such holds investments in its subsidiaries DermaTools Biotech GmbH (59%) and CytoPharma GmbH (47%).

Contact:

CytoTools AG
Dr. Mark Andre Freyberg
Klappacher Str. 126
D-64285 Darmstadt
Tel.: +49-6151-95158-12
Fax: +49-6151-95158-13
E-Mail: freyberg@cytotools.de

UBJ. GmbH
Ingo Janssen
Haus der Wirtschaft
Kapstadtring 10
D-22297 Hamburg
Tel.: +49-40-6378-5410
Fax: +49-40 6378-5423
E-Mail: ir@ubj.de